Heparin Articles
Pharming reports 1999 revenues up 54%
29 March 2000
Weston looking to raise L50 million
28 March 2000
Roche's lamifiban fails to meet endpoint
16 March 2000
Genentech unveils new trials for tenecteplase
15 March 2000
Product pipeline pushes Pharming shares
6 March 2000
Texas' Novastan is "approvable," says FDA
24 February 2000
Unstable angina, IBD market forecasts
15 February 2000
Pharmacia & Upjohn and Monsanto both post strong results for 1999
11 February 2000
Unstable angina sales forecast to 2008
19 January 2000
Genzyme Transgenics' antithrombin III, signs deal with Alexion
13 January 2000
Incara starts trials of IBD drug
5 November 1999
1st Angiomax approval in New Zealand
4 November 1999
P&U continues turnaround, looking for 1999 double-digit growth
29 October 1999
ICN to launch Knoll's Clivarine
26 October 1999
Antiplatelet/thrombolytic combination: way forward for MI therapy?
1 September 1999
Texas submits corrected amendment to Novastan NDA
26 August 1999
R-PR opens $50 mill plant in Singapore
21 July 1999
HMR files Refludan for new indication
15 July 1999
DuPont files for new LMWH in USA (updated)
6 July 1999
DuPont files for Innohep in USA
2 July 1999
Pharming starts lactoferrin trial
1 July 1999
Fragmin cleared for angina in USA
3 June 1999
Intercardia to test IBS candidate
13 May 1999
P&U pursues novel antibiotics in $30m deal
7 April 1999
Weston Medical raises L8 million for Intraject
29 March 1999
Texas resubmits Novastan to FDA
29 March 1999
OASIS-2 data support Refludan efficacy in UA
15 February 1999
P&U posts strong growth for 1998
12 February 1999
Weston Medical signs Intraject deal with P&U
4 February 1999
Oral heparin effective in Phase II
14 January 1999
Sanofi-Synthelabo Merger Strong In Cardio, CNS
10 December 1998
Aventis Pipeline Rich In Near-Term Prospects
10 December 1998
The Medicines Co Start Hirulog Phase III Trial
8 December 1998
Sanofi's Fraxiparine DVT Treatment Update
2 December 1998
Pharming And Gem In Lactoferrin Venture
2 December 1998
Plavix/Aspirin Combination To Be Studied
18 November 1998
TIMI 11B Reinforces Enoxaparin Role In UA
18 November 1998
Ibex Resume Phase III Neutralase Trial
2 November 1998
FDA Rejects The Medicine Company's Hirulog
29 October 1998
Emisphere Technologies' Phase I oral heparin results
22 October 1998
R-PR Drops Klerval From Development
16 October 1998
Synthelabo Pipeline
15 October 1998
Fast Growth Seen For BASF's Pharma Unit
7 October 1998
OASIS 2 Supports Refludan Utility In Unstable Angina
1 September 1998
Altana Expands Overseas Thanks To Pantoprazole
13 August 1998
Sanofi Produces Strong First-Half Sales Growth
24 July 1998
Intercardia Licenses Italian IBD Drug
23 July 1998
HMR's Refludan Launched In The USA
9 July 1998
R-PR Licenses Novartis' Revasc
30 June 1998
Sanofi's Eloxatin Gearing Up For Global Roll-Out
30 June 1998
Rhone-Poulenc Rorer Cuts More Jobs
25 June 1998
Integrilin Launched In First Market, The USA
4 June 1998
Emisphere Initiates Ph II Oral Heparin Trial
28 May 1998
Aggrastat, Integrilin First ReoPro Competitors
21 May 1998
Genzyme Starts Pivotal Antithrombin III Trials
21 May 1998
Texas' Novastan Is "Non-Approvable"
14 May 1998
SB Defends Independence On Strong R&D Grounds
23 April 1998
R-PR Expanding Lovenox Production
16 April 1998
Aggrastat Backed For Unstable Angina
14 April 1998
Integrilin "Approvable" In USA For Unstable Angina
8 April 1998
Argatroban In Acute Myocardial Infarction
8 April 1998
Combining Drugs With Interventional Cardiology
8 April 1998
Synthelabo Predicts Strong Opportunities For Growth
6 April 1998
DuPont Merck Gains US Rights To Leo's Innohep
2 April 1998
FDA Advisory Committee Meetings
2 April 1998
R-PR's Lovenox Cleared In USA For Angina
31 March 1998
UK Launch For Refludan; Angina Filing By End-98?
19 March 1998
Refludan Filed For Angina By Year-End?
16 March 1998
Bad Times Soon Over, Says Hoechst Marion Roussel
12 March 1998
Intercardia To License OP2000
12 March 1998
FDA Approves HMR's Refludan
11 March 1998
Sanofi Pharma Sales Held Back In West Europe, But Up 10%
4 February 1998
Highlights Of Astra's Pipeline Presentation
30 January 1998
Product News In Brief
29 January 1998
Elan Moves Forward With MS Antibody
29 January 1998
More Approvals For Lovenox In Angina
14 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
New Clinical Trials In Brief
4 December 1997
Phase I With Benestent
25 November 1997
Vascular Therapeutics' Vasoflux in Phase II
24 November 1997
ReoPro As Adjunct To Thrombolysis; TIMI 14
20 November 1997
Adenosine + Thrombolysis Cuts Infarcts
18 November 1997
Synthelabo's "Excellent" Year; Will Acquire Firm
21 October 1997
Enoxaparin Approved For Angina And MI
25 September 1997
New Studies At European Cardiology Meeting
15 September 1997
COR Therapeutics Boosted By Integrilin Data
28 August 1997
ROXIS - More Support For Antibiotics In Heart Disease
13 August 1997
Normiflo Launched In USA; First Market
7 August 1997
1st Approval For Novartis' Exelon; 2nd For Revasc
7 August 1997
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
